Clinical Trial Update: VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Velcade (bortezomib) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Idamycin (idarubicin)
• Velcade (bortezomib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Leukemia | Phase 1 | Status: COMPLETED